ESTRO 2022 - Abstract Book

S1182

Abstract book

ESTRO 2022

Results The average age was 63.0 ± 7.5 years and median pre-treatment PSA was 6.55 (IQR 4.94). 1,473 (93.2%) and 108 (6.8%) underwent RP and RT, respectively. RP patients were younger, had lower pre-PSA, lower BMI, and lower risk disease. At 3.4 ± 2.7 years follow-up, 323 (20.4%) experienced BF. When stratified by statin use, BF overall and within 1, 3, and 5 years were not different. Time to BF was lower in patients using statins (1.8 ± 1.9 years vs. 2.4 ± 2.6 years; p=0.016). These results persisted in multivariate analysis, wherein statin use was not associated with BF but was associated with shorter time to BF

.

Conclusion Overall, statin use was not associated with reduced risk of BF in RP or RT patients. However, for patients with BF, statin use was associated with a decreased time to BF. Future investigations are warranted to further elucidate impact of statin use on PCa recurrence.

PO-1396 PSMA-PET management of prostate cancer patients relapsing after RP plus prostate-bed radiotherapy

V. Chiofalo 1 , G.C. Iorio 1 , I. Bonavero 1 , S. Bartoncini 1 , V. Richetto 2 , S. Grimaldi 3 , S. Dall'Armellina 3 , D. Deandreis 4 , B. Lillaz 5 , M. Oderda 5 , P. Gontero 5 , A. Guarneri 1 , U. Ricardi 1 1 University of Turin, Department of Oncology, Turin, Italy; 2 University of Turin, Department of Medical Physics, Turin, Italy; 3 University of Turin, Department of Medical Sciences, Nuclear Medicine, Turin, Italy; 4 University of Turin, Deparment of Medical Sciences, Nuclear Medicine, Turin, Italy; 5 University of Turin, Department of Surgical Sciences, Urology, Turin, Italy

Purpose or Objective